CASI Pharmaceuticals, Inc. (CASI): Price and Financial Metrics

CASI POWR Grades

• CASI scores best on the Growth dimension, with a Growth rank ahead of 80.21% of US stocks.
• The strongest trend for CASI is in Momentum, which has been heading down over the past 52 weeks.
• CASI's current lowest rank is in the Momentum metric (where it is better than 4.19% of US stocks).

CASI Stock Summary

• The ratio of debt to operating expenses for CASI Pharmaceuticals Inc is higher than it is for about just 6.79% of US stocks.
• Revenue growth over the past 12 months for CASI Pharmaceuticals Inc comes in at 121.49%, a number that bests 94.12% of the US stocks we're tracking.
• The volatility of CASI Pharmaceuticals Inc's share price is greater than that of 89.46% US stocks with at least 200 days of trading history.
• Stocks that are quantitatively similar to CASI, based on their financial statements, market capitalization, and price volatility, are CTSO, CLIR, TUFN, AMST, and APDN.
• Visit CASI's SEC page to see the company's official filings. To visit the company's web site, go to www.casipharmaceuticals.com.

CASI Valuation Summary

• CASI's price/sales ratio is 10.2; this is 10.13% lower than that of the median Healthcare stock.
• CASI's price/sales ratio has moved down 40 over the prior 243 months.
• CASI's price/earnings ratio has moved down 0.6 over the prior 243 months.

Below are key valuation metrics over time for CASI.

CASI Growth Metrics

• The 2 year net income to common stockholders growth rate now stands at -265.69%.
• Its year over year net income to common stockholders growth rate is now at -16.05%.
• The 3 year net cashflow from operations growth rate now stands at -394.4%.

CASI's revenue has moved up $21,962,000 over the prior 30 months.

The table below shows CASI's growth in key financial areas (numbers in millions of US dollars).

Date	Revenue	Operating Cash Flow	Net Income to Common Stock
2021-06-30	21.962	-30.203	-51.981
2021-03-31	17.471	-29.253	-53.729
2020-12-31	15.141	-25.886	-48.287
2020-09-30	11.663	-22.672	-46.987
2020-06-30	10.208	-20.59041	-39.68
2020-03-31	7.537	-22.65823	-46.29917

CASI's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.

• CASI has a Quality Grade of F, ranking ahead of 3.6% of graded US stocks.
• CASI's asset turnover comes in at 0.158 -- ranking 218th of 682 Pharmaceutical Products stocks.
• DRNA, RARE, and ALNY are the stocks whose asset turnover ratios are most correlated with CASI.

The table below shows CASI's key quality metrics over time.